Intervention

Cadonilimab (AK104)

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4
Recruiting3
Common conditions5
Lead sponsors shown4
Advertisement

Clinical trials

4 shown
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)NCT06401005 · 2024-11-28
RECRUITING
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCNCT06617416 · 2024-11-12
RECRUITING
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed ImmunotherapyNCT06467500 · 2024-03-01
RECRUITING
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLCNCT06448910 · 2024-07-01
ACTIVE_NOT_RECRUITING

Trial status mix

RECRUITING3
ACTIVE_NOT_RECRUITING1

Phase mix

PHASE23
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.